The closing price of Chimerix Inc (NASDAQ: CMRX) was $0.91 for the day, down -4.80% from the previous closing price of $0.96. On the day, 506516 shares were traded.
Ratios:
Our analysis of CMRX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 10.25 and its Current Ratio is at 10.25. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Robert W. Baird on May 23, 2023, initiated with a Outperform rating and assigned the stock a target price of $7.
On September 07, 2022, CapitalOne started tracking the stock assigning a Overweight rating and target price of $7.
On April 29, 2021, Maxim Group started tracking the stock assigning a Buy rating and target price of $20.Maxim Group initiated its Buy rating on April 29, 2021, with a $20 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 14 ’24 when Jakeman David sold 2,660 shares for $1.04 per share. The transaction valued at 2,777 led to the insider holds 141,232 shares of the business.
LaSpaluto Michelle sold 1,940 shares of CMRX for $2,023 on Feb 14 ’24. The CHIEF FINANCIAL OFFICER now owns 110,999 shares after completing the transaction at $1.04 per share. On Feb 14 ’24, another insider, Andriole Michael T., who serves as the PRESIDENT AND CEO of the company, sold 1,744 shares for $1.04 each. As a result, the insider received 1,809 and left with 447,021 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 254.97 while its Price-to-Book (P/B) ratio in mrq is 0.42.
Stock Price History:
Over the past 52 weeks, CMRX has reached a high of $1.57, while it has fallen to a 52-week low of $0.88.
Shares Statistics:
A total of 88.93M shares are outstanding, with a floating share count of 79.36M. Insiders hold about 11.04% of the company’s shares, while institutions hold 46.03% stake in the company.
Earnings Estimates
The firm’s stock currently is rated by Catalyst Pharmaceuticals, Inc. analysts. The consensus estimate for the next quarter is $5.54, with high estimates of $1.92 and low estimates of $0.91.
Analysts are recommending an EPS of between $Healthcare and $Healthcare for the fiscal current year, implying an average EPS of $Healthcare.
